Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker
JournalBioMed Research International
MetadataShow full item record
AbstractImmunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demonstrated a relevant clinical value in a large number of solid tumors, leading to an improvement of progression free survival and overall survival in comparison to standard chemotherapy. However, across different solid malignancies, the immune-checkpoints inhibitors efficacy is limited to a relative small number of patients and, for this reason, the identification of positive or negative predictive biomarkers represents an urgent need. Despite the expression of PD-L1 was largely investigated in various malignancies, (i.e., melanoma, head and neck malignancies, urothelial and renal carcinoma, metastatic colorectal cancer, and pancreatic cancer) as a biomarker for ICB treatment-patients selection, it showed an important, but still imperfect, role as positive predictor of response only in nonsmall cell lung cancer (NSCLC). Importantly, other tumor and/or microenvironments related characteristics are currently under clinical evaluation, in combination or in substitution of PD-L1 expression. In particular, tumor-infiltrating immune cells, gene expression analysis, mismatch- repair deficiency, and tumor mutational landscape may play a central role in predicting clinical benefits of CTLA-4 and/or PD-1/PD-L1 checkpoint inhibitors. In this review, we will focus on the clinical evaluation of emerging biomarkers and how these may improve the naïve vision of a single- feature patients-based selection. Copyright 2019 Diego Signorelli et al.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85065577027&doi=10.1155%2f2019%2f9056417&partnerID=40&md5=559a4ef4a98f6284035df8a41616dbb6; http://hdl.handle.net/10713/10711
- Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
- Authors: Hayashi H, Nakagawa K
- Issue date: 2020 May
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
- Authors: Mahoney KM, Freeman GJ, McDermott DF
- Issue date: 2015 Apr 1
- Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
- Authors: Atkins MB, Clark JI, Quinn DI
- Issue date: 2017 Jul 1
- The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
- Authors: Takada K, Toyokawa G, Shoji F, Okamoto T, Maehara Y
- Issue date: 2018 Mar
- Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
- Authors: Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ
- Issue date: 2016 Sep